A mid-stage trial of oral ketamine tablets has shown promising results in treatment-resistant depression (TRD), setting up a phase 3 programme and a possible challenge to Johnson & Johnson’s Spravato.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback